[HTML][HTML] The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation–Positive Non–Small cell lung …
Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …
Newer-generation EGFR inhibitors in lung cancer: how are they best used?
T Le, DE Gerber - Cancers, 2019 - mdpi.com
The FLAURA trial established osimertinib, a third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …
Targeting EGFR in lung cancer: current standards and developments
A Díaz-Serrano, P Gella, E Jiménez, J Zugazagoitia… - Drugs, 2018 - Springer
Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …
Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer
TA Barnes, GM O'Kane, MD Vincent… - Frontiers in oncology, 2017 - frontiersin.org
Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …
[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
[HTML][HTML] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
I Okamoto, S Morita, N Tashiro, F Imamura, A Inoue… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
Treatment of non-small cell lung cancer with EGFR-mutations
K Yoneda, N Imanishi, Y Ichiki, F Tanaka - Journal of UOEH, 2019 - jstage.jst.go.jp
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
N Girard - Future Oncology, 2018 - Taylor & Francis
Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Simple Summary The management of non-small cell lung cancer with a common EGFR
mutation has evolved over the past decades. While frontline use of second-or third …
mutation has evolved over the past decades. While frontline use of second-or third …